In addition to older age, significant differences in Group 1 versus Group 2 included elevated IgA/IgG SARS-CoV-2-specific antibody levels and an increased duration of COVID-19 symptoms (Figure 1B and Supplemental Figure 1). This evidence concerns the gene CD79A and COVID-19.